40 results
8-K
EX-99.2
i06 r9spfzfe4l
3 Aug 21
Regulation FD Disclosure
4:36pm
8-K
EX-99.3
b781o4
3 Aug 21
Regulation FD Disclosure
4:36pm
8-K
EX-99.1
wquoznv3 ymo
3 Aug 21
Cassava Sciences Reports Second Quarter 2021 Financial Results
8:45am
8-K
EX-99.1
p1bnj cic
21 Apr 21
Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release
8:45am
8-K
EX-10.1
dj73svo3pb7g
11 Mar 21
Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam
4:59pm
8-K
EX-99.1
t3s 29jez
8 Feb 21
Regulation FD Disclosure
4:09pm
8-K
EX-99.2
yvx8f0onu8
8 Feb 21
Regulation FD Disclosure
4:09pm
8-K
EX-99.1
m95nngbvv27b l9f0ag
6 Jan 21
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
4:39pm
8-K
EX-99.1
q62ubiu7
14 Sep 20
Regulation FD Disclosure
4:01pm
8-K
EX-99.2
zdacudc0swiymde
14 Sep 20
Regulation FD Disclosure
4:01pm
8-K
EX-99.1
id7hs7h3qim7c3rn
12 Aug 20
Cassava Sciences Announces Second Quarter 2020 Financial Results and Mid-year Business Review
8:30am
8-K
EX-99.2
e0srg2ggvs28d
3 Jun 20
Regulation FD Disclosure
5:29pm
8-K
EX-99.1
5kpgy50
15 May 20
Top-line Results from a Phase 2b Study of PTI-125 in Alzheimer’s Disease Does Not Meet Primary Endpoint
8:20am